MAb52-4.2-ADC

MAb52-4.2-ADC is a first-in-class antibody-drug conjugate (ADC) targeting SLC3A2 (also known as CD98 heavy chain or 4F2hc), a transmembrane glycoprotein overexpressed in various solid and hematologic malignancies. Developed by MedAbome, Inc., the drug consists of a humanized monoclonal antibody (MAb52-4.2) that selectively recognizes a tumor-associated conformational epitope of SLC3A2. This antibody is conjugated to the cytotoxic payload monomethyl auristatin E (MMAE) via a protease-cleavable MC-Vc-PAB linker, with a drug-to-antibody ratio (DAR) of 4. In preclinical studies, MAb52-4.2-ADC demonstrated potent anti-proliferative activity and significant tumor regression in xenograft models of triple-negative breast cancer (TNBC), non-small cell lung cancer (NSCLC), and gastric cancer, while showing minimal cross-reactivity with normal tissues.

Other names

anti-SLC3A2 ADCanti-SLC-3A2 ADCanti-SLC 3A2 ADC